SequelSEC

Design Therapeutics, Inc. DSGN

Pharmaceutical Preparations · CIK 0001807120 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$79.47M
Fiscal year ended 2025-12-31
Free cash flow
-$54.55M
Fiscal year ended 2025-12-31

Design Therapeutics, Inc. (DSGN) reported revenue of $0 and net income of -$69.79M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Design Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Design Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312020-12-31
Revenue$0$0$226.00K
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$79.47M-$62.38M-$8.33M
Net income-$69.79M-$49.59M-$8.28M
Research & development$59.13M$44.35M$6.06M
Weighted-average diluted sharesshares 57.33Mshares 56.59MUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expense$0$0Unavailable
Diluted EPS$-1.22$-0.88Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$20.34M$18.03M$2.50M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Design Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312020-12-31
Cash & equivalents$16.86M$22.56M$2.38M
Total assets$226.20M$252.09M$36.52M
Current assets$223.78M$248.04M$36.23M
Total liabilities$13.70M$10.00M$2.48M
Current liabilities$13.06M$8.46M$2.33M
Total equity incl. NCI$212.50M$242.10M-$11.32M
Temporary (mezzanine) equityUnavailableUnavailable$45.36M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$2.31M$2.19M$1.40M

Cash flow

Design Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312020-12-31
Operating cash flow-$54.36M-$43.10M-$8.67M
Capital expenditures$193.00K$340.00K$76.00K
Investing cash flow$22.91M$43.96M-$33.56M
Financing cash flow$25.74M$513.00K$44.53M
Net change in cash-$5.71M$1.36M$2.30M
Stock-based compensation$14.55M$13.07M$450.00K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Design Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312020-12-31
Free cash flow-$54.55M-$43.44M-$8.74M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailable-3685.8%
FCF marginUnavailableUnavailable-3869.5%
SBC / revenueUnavailableUnavailable199.1%
Current ratio17.14x29.31x15.55x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailable-3663.7%
R&D / revenueUnavailableUnavailable2681.4%
CapEx / revenueUnavailableUnavailable33.6%
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open DSGN in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-03View SEC filing
10-Q · Filed 2026-04-28View SEC filing
10-K · Filed 2026-03-09View SEC filing
10-Q · Filed 2025-11-05View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-07View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.